ReviewDrug discovery today2022
Efficacy of repurposed antiviral drugs: Lessons from COVID-19.
Review in Drug discovery today, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir-ritonavir in patients with COVID-19.British journal of clinical pharmacology · 2026Trial
- A late-stage multi-dimensional intervention rescues lethal viral pneumonia in an aged hamster model.Molecular biomedicine · 2026Article
- Global Burden of Upper Airway Infections: Epidemiology, Current Challenges and Future Perspectives.Infectious disease reports · 2026Review
- Review
- Reactive oxygen species promotion drives auranofin's antiviral activity against hepatitis E virus.Journal of virology · 2026Article
- Membrane-Targeting Antivirals.International journal of molecular sciences · 2025Review
- Targeting mutation sites in the omicron variant of SARS-CoV-2 as potential therapeutic strategy against COVID-19 by antiretroviral drugs.Toxicology reports · 2024Article
- Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies.Molecules (Basel, Switzerland) · 2024Review
- Review and perspective on bioinformatics tools using machine learning and deep learning for predicting antiviral peptides.Molecular diversity · 2024Review
- Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents.Biomolecules · 2024Review
- Identification of Dual Inhibitors Targeting Main Protease (MACS medicinal chemistry letters · 2024Article
- Development of complemented comprehensive networks for rapid screening of repurposable drugs applicable to new emerging disease outbreaks.Journal of translational medicine · 2023Article
- Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation.BMC chemistry · 2023Article
- Significant Broad-Spectrum Antiviral Activity of Bi121 against Different Variants of SARS-CoV-2.Viruses · 2023Article
- Drug discovery through Covid-19 genome sequencing with siamese graph convolutional neural network.Multimedia tools and applications · 2023Article
- Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2.European journal of medicinal chemistry · 2023Review
- SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations.Computers in biology and medicine · 2023Article
- Recent updates on the biological efficacy of approved drugs and potent synthetic compounds against SARS-CoV-2.RSC advances · 2023Review
- Tripterin liposome relieves severe acute respiratory syndrome as a potent COVID-19 treatment.Signal transduction and targeted therapy · 2022Article
- Drug repurposing: An effective strategy to accelerate contemporary drug discovery.Drug discovery today · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical, social, and economic impacts of the coronavirus disease 2019 (COVID-19) pandemic, originated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have motivated a massive search and investment to find treatments for this new disease. Repurposing drugs has been an appealing strategy for the rapid translation of in vitro and ex vivo drug discovery to the clinic. Several repurposed drugs have been assessed clinically, but no effective repurposed antiviral has been identified so far. Of note, no effective treatments for COVID-19 or for any other viral disease have been found by repurposing drugs identified through hypothesis-free screens. Here, I discuss whether drug repurposing is the best strategy for developing effective therapies to eradicate COVID-19 and other viral human infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.